Patent: 9,248,172

Try a free trial

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,248,172

Title:	Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
Abstract:	The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an .alpha.-2-macroglobulin (.alpha.2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an .alpha.2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or .alpha.2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.
Inventor(s):	Srivastava; Pramod K. (Avon, CT), Li; Zihai (Mount Pleasant, SC)
Assignee:	University of Connecticut Health Center (Farmington, CT)
Application Number:	14/043,666
Patent Claims:	see list of patent claims

Details for Patent 9,248,172

Glossary

Subscribe to access the full database, or request a copy of the full page.
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26	Try a Free Trial	University of Connecticut Health Center (Farmington, CT)	2022-04-25	RX		search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	002	2004-02-26	Try a Free Trial	University of Connecticut Health Center (Farmington, CT)	2022-04-25	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 9,248,172

Subscribe to access the full database, or request a copy of the full page.
Country	Patent Number	Publication Date
Australia	2003231098	Nov 10, 2003
Canada	2483449	Nov 06, 2003
China	1819842	Aug 16, 2006
European Patent Office	1572083	Sep 14, 2005
European Patent Office	1572083	Sep 24, 2008
Israel	164799	Dec 18, 2005
Japan	2006501147	Jan 12, 2006
>Country	>Patent Number	>Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.